Max Scherer

Dr. Max Scherer


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2015 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
NPNikola Pluym
Nikola Pluym
GGGerhard Gilch
Gerhard Gilch
GSGerhard Scherer
Gerhard Scherer
MSMax Scherer
Max Scherer

1 March 2014 in Journal of Chromatography B
Verified
Journal Article
Closed access
MPMarkus Piller
Markus Piller
GGGerhard Gilch
Gerhard Gilch
GSGerhard Scherer
Gerhard Scherer
MSMax Scherer
Max Scherer

5 February 2014 in Journal of Proteome Research
Verified
Journal Article
Open access
DMDaniel C. Mueller
Daniel C. Mueller
MPMarkus Piller
Markus Piller
RNReinhard Niessner
Reinhard Niessner
MSMax Scherer
Max Scherer
GSGerhard Scherer
Gerhard Scherer
A GC-TOF-MS method was developed and validated for a metabolic fingerprinting in saliva of smokers and nonsmokers. We validated the method by spiking 37 different metabolites and 6 internal standards to saliva between 0.1 μM and 2 mM. Intraday coefficients of variation (CVs) (accuracies) were on average, 11.9% (85.8%), 8.2% (88.9%), and 10.0% (106.7%) for the spiked levels 25, 50, and 200 μM, respectively (N = 5). Interday CVs (accuracies) were 12.4% (97%), 18.8% (95.5%), and 17.2% (105.9%) for the respective levels of 25, 50, and 200 μM (N = 5). The method was applied to saliva of smokers and nonsmokers, obtained from a 24 h diet-controlled clinical study, in order to identify biomarkers of endogenous origin, which could be linked to smoking related diseases. Automated peak picking, integration, and statistical analysis were conducted by the software tools MZmine, Metaboanalyst, and PSPP. We could identify 13 significantly altered metabolites in smokers (p < 0.05) by matching them against MS libraries and authentic standard compounds. Most of the identified metabolites, including tyramine, adenosine, and glucose-6-phosphate, could be linked to smoking-related perturbations and may be associated with established detrimental effects of smoking.

11 March 2022 in Current Research in Toxicology
Verified
Journal Article
Open access
GSGerhard Scherer
Gerhard Scherer
JMJanina Mütze
Janina Mütze
NPNikola Pluym
Nikola Pluym
MSMax Scherer
Max Scherer
• Nicotine uptake doses from various products show a large overlap between each other. • Combustible cigarettes and oral tobacco products are at the high end of the nicotine uptake doses. • Simple models for daily amounts of nicotine intake can predict the nicotine doses for most product users. • Larger deviations were observed for smokers and users of heated tobacco products. • The most probable reason for these deviations are differences in parameters for puffing and inhalation and actual behavior of the users.


1 November 2022 in ACS Omega
Verified
Journal Article
Open access
GSGerhard Scherer
Gerhard Scherer
KRKirsten Riedel
Kirsten Riedel
NPNikola Pluym
Nikola Pluym
MSMax Scherer
Max Scherer
Aromatic amines such as ortho-toluidine (o-Tol), 2-aminonaphthalene (2-AN), and 4-aminobiphenyl (4-ABP) are human bladder carcinogens and occur at various workplaces, in ambient air, in food products, as well as in tobacco smoke. In a clinical study comprising a period of 74 h under confinement, we investigated the exposure to these three aromatic amines as well as to 3-aminobiphenyl (3-ABP) by measuring them in urine of habitual users of combustible cigarettes (CCs), electronic cigarettes (ECs), heated tobacco products (HTPs), oral tobacco (OT), and nicotine replacement therapy products (NRTs). Non-users (NU) of any tobacco/nicotine products served as (negative) control group. Smokers (CC) exhibited the highest levels for all four aromatic amines measured, significantly elevated compared to NU and non-CC users. Urinary levels in users of EC, HTP, NRT (mostly nicotine gum), and OT (mostly snus) were not significantly different from those in NU. Users of HTP showed slightly elevated urinary excretion levels of o-Tol, 3-ABP, and 4-ABP compared to some other non-CC groups. Dose markers such as daily consumption, urinary nicotine equivalents (Nequ), and plasma cotinine (CotP) were found to be consistently and significantly correlated with the excretion of aromatic amines for smokers (CC) only. Excretion levels of 3- and 4-ABP in smokers were significantly lower in the urine collected overnight compared to that collected during the day, which is just the opposite of what we observed for other biomarkers in this study. The possible reason for this observation is discussed. In conclusion, in contrast to smoking of CCs, the use of ECs, HTPs, nicotine gum, and oral tobacco was not observed to be associated with significant exposure to the aromatic amines o-Tol, 2-AN, 3-ABP, and 4-ABP. The observed slight increase in o-Tol, 3-ABP, and 4-ABP excretions in HTP users has to be verified in larger studies.